Programa de cáncer de pulmón - Ensayos clínicos - Mayo Clinic

COVID-19 consejos información actualizada y opciones de vacunas

Infórmate sobre la COVID-19 y las vacunas contra esta enfermedad, y conoce las novedades para pacientes y visitantes de Mayo Clinic. Para navegación del sitio Para acceso a contenido Este contenido no tiene una versión en inglésEste contenido no tiene una versión en árabe Search Pida una consulta Para encontrar un doctor Para encontrar trabajo Para donar Acceso a su cuenta de paciente Español English العربية 简体中文 Twitter Facebook Pinterest YouTube Menú Solicite una Consulta Departamentos y centros Centros y departamentos médicos

Programa de cáncer de pulmón

Ensayos clínicos

A continuación, se enumeran los ensayos clínicos actuales.
34 estudios en Programa de cáncer de pulmón
(solo estudios abiertos). Filtra esta lista de estudios por sede, estatus, etc.

A Study to Evaluate a Health and Wellness Coaching Model in Support of Caregivers of Patients with Advanced Lung Cancers

Jacksonville, Fla. Piloting the BeWell360-CG model, in conjunction with usual care delivery for lung cancer patients in Palliative Care, will longitudinally improve the wellbeing and quality of life of care givers within and outside of clinical care settings, in such a way as to positively impact the quality of care of patients themselves. We hypothesize that PC staff trained in the BeWell360-CG will be able to identify the most common CG-centric needs and guide CGs to improve their QoL and personal wellbeing. In doing so, we further hypothesize that there will be an improvement in patient-reported and quality of care outcomes. The objective of this proposal is to pilot a novel, scalable, user-friendly HWC care model– the BeWell360-CG— that is embedded and integrated as part of a palliative approach to care for CGs of patients with advanced lung cancer.

A Study to Evaluate Exemestane in Post-Menopausal Women with Non-Small Cell Lung Cancer NSCLC

Albert Lea, Minn., Mankato, Minn. This study is being conducted to see if adding Exemestane to the immune checkpoint blockade can slow disease progression in post-menopausal women with non-small cell lung cancer.

A Study to Evaluate Immunotherapy for Non-Small Cell Lung Cancer

Scottsdale/Phoenix, Ariz. The primary objectives of this study are to evaluate safety/tolerability and immunogenicity of IMU-201 as monotherapy and in combination with an immune checkpoint inhibitor (ICI) or an ICI and chemotherapy in participants with advanced NSCLC tumors that are positive for PD-L1, and to identify the Optimal Biological Dose (OBD) of IMU-201 as monotherapy and in combination with an ICI, or an ICI and chemotherapy, in participants with advanced NSCLC tumors that are positive for PD-L1.

A Global Study to Assess the Effects of MEDI4736 Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer

Scottsdale/Phoenix, Ariz. This study is a Phase III, randomised, open label, multi-centre study assessing the efficacy and safety of MEDI4736 versus Standard of Care in NSCLC patients with PD-L1 positive tumours and the combination of MEDI4736 plus tremelimumab (MEDI4736+treme) versus Standard of Care in NSCLC patients with PD-L1-negative tumours in the treatment of male and female patients with locally advanced or metastatic NSCLC (Stage IIIB-IV), who have received at least 2 prior systemic treatment regimens including 1 platinum-based chemotherapy regimen for NSCLC. Patients with known EGFR (Epidermal growth factor receptor) tyrosine kinase (TK) activating mutations and anaplastic lymphoma kinase (ALK) rearrangements are not eligible for the study (prospective testing is not planned within this study). The Standard of Care options are: an EGFR tyrosine kinase inhibitor (erlotinib [TARCEVA®]), gemcitabine or vinorelbine (NAVELBINE®).

A Study to Evaluate Whether Probiotics for Gut Microbiome Will Target Cancer Immune Microenvironment in Breast and Lung Cancer

Jacksonville, Fla. The purpose of this study is to evaluate whether engineering gut microbiome using probiotics will alter host immunological response to breast and lung cancers.

A Study to Evaluate the Safety Tolerability Pharmacokinetics and Anti-tumor Activity of WSD0922-FU

Rochester, Minn., Scottsdale/Phoenix, Ariz., Jacksonville, Fla. The purpose of this study is to determine the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of WSD0922-FU in subjects with recurrent glioblastoma, IDH wildtype (GBM), anaplastic astrocytoma, IDH wildtype (AA) and CNS metastases of non-small cell lung cancer (NSCLC).

A Study to Evaluate Fractionated Radiation Therapy Utilizing GRID Therapy for Locally-advanced Bulky Tumors

Rochester, Minn., Jacksonville, Fla. The purpose of this research is to study radiographic control at the 3 month time-point, the side effects (good & bad), survival outcomes and proof of this idea in patients who have had grid therapy for locally advanced bulky tumors of the heat and neck, thorax, abdomen and extremities.

Evaluate the Safety Tolerability Pharmacokinetics and Preliminary Evidence of Antitumor Activity of JAB-3312 Based Combination Therapies in Adult Patients with Advanced Solid Tumors

Jacksonville, Fla., Rochester, Minn., Scottsdale/Phoenix, Ariz. The purpose of this study is to demonstrate the safety and tolerability of JAB-3312 in combination with anti-PD-1 mAb or MEKi or KRASi or EGFR-TKI in patients with advanced solid tumors.

Profiling of Lung Cancer for Identification of Treatment Targets and Strategies

Jacksonville, Fla. The purpose of this research trail is to study the genetic alteration/mutation and immune profiling in surgical resected Non-small Cell Lung Cancer (NSCLC) tumor samplesand to investigate the correlation between genetic alteration/mutation status and tumor immune micro-environment.

Crizotinib in Treating Patients with Stage IB-IIIA Non-small Cell Lung Cancer that has been Removed by Surgery and ALK Fusion Mutations An ALCHEMIST Treatment Trial

Scottsdale/Phoenix, Ariz., Rochester, Minn. This randomized phase III trial studies how well crizotinib works and compares it to placebo in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called ALK. Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Tumors with this mutation may respond to treatments that target the mutation, such as crizotinib. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. It is not yet known if crizotinib may be an effective treatment for treating non-small cell lung cancer with an ALK fusion mutation. Solicite una Consulta en Mayo Clinic Noticias de Mayo ClinicInvestigación Feb. 11, 2022 Comparte en: FacebookTwitter A continuación, se enumeran los ensayos clínicos actuales.
34 estudios en Programa de cáncer de pulmón
(solo estudios abiertos). Filtra esta lista de estudios por sede, estatus, etc.

A Study to Evaluate a Health and Wellness Coaching Model in Support of Caregivers of Patients with Advanced Lung Cancers

Jacksonville, Fla. Piloting the BeWell360-CG model, in conjunction with usual care delivery for lung cancer patients in Palliative Care, will longitudinally improve the wellbeing and quality of life of care givers within and outside of clinical care settings, in such a way as to positively impact the quality of care of patients themselves. We hypothesize that PC staff trained in the BeWell360-CG will be able to identify the most common CG-centric needs and guide CGs to improve their QoL and personal wellbeing. In doing so, we further hypothesize that there will be an improvement in patient-reported and quality of care outcomes. The objective of this proposal is to pilot a novel, scalable, user-friendly HWC care model– the BeWell360-CG— that is embedded and integrated as part of a palliative approach to care for CGs of patients with advanced lung cancer.

A Study to Evaluate Exemestane in Post-Menopausal Women with Non-Small Cell Lung Cancer NSCLC

Albert Lea, Minn., Mankato, Minn. This study is being conducted to see if adding Exemestane to the immune checkpoint blockade can slow disease progression in post-menopausal women with non-small cell lung cancer.

A Study to Evaluate Immunotherapy for Non-Small Cell Lung Cancer

Scottsdale/Phoenix, Ariz. The primary objectives of this study are to evaluate safety/tolerability and immunogenicity of IMU-201 as monotherapy and in combination with an immune checkpoint inhibitor (ICI) or an ICI and chemotherapy in participants with advanced NSCLC tumors that are positive for PD-L1, and to identify the Optimal Biological Dose (OBD) of IMU-201 as monotherapy and in combination with an ICI, or an ICI and chemotherapy, in participants with advanced NSCLC tumors that are positive for PD-L1.

A Global Study to Assess the Effects of MEDI4736 Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer

Scottsdale/Phoenix, Ariz. This study is a Phase III, randomised, open label, multi-centre study assessing the efficacy and safety of MEDI4736 versus Standard of Care in NSCLC patients with PD-L1 positive tumours and the combination of MEDI4736 plus tremelimumab (MEDI4736+treme) versus Standard of Care in NSCLC patients with PD-L1-negative tumours in the treatment of male and female patients with locally advanced or metastatic NSCLC (Stage IIIB-IV), who have received at least 2 prior systemic treatment regimens including 1 platinum-based chemotherapy regimen for NSCLC. Patients with known EGFR (Epidermal growth factor receptor) tyrosine kinase (TK) activating mutations and anaplastic lymphoma kinase (ALK) rearrangements are not eligible for the study (prospective testing is not planned within this study). The Standard of Care options are: an EGFR tyrosine kinase inhibitor (erlotinib [TARCEVA®]), gemcitabine or vinorelbine (NAVELBINE®).

A Study to Evaluate Whether Probiotics for Gut Microbiome Will Target Cancer Immune Microenvironment in Breast and Lung Cancer

Jacksonville, Fla. The purpose of this study is to evaluate whether engineering gut microbiome using probiotics will alter host immunological response to breast and lung cancers.

A Study to Evaluate the Safety Tolerability Pharmacokinetics and Anti-tumor Activity of WSD0922-FU

Rochester, Minn., Scottsdale/Phoenix, Ariz., Jacksonville, Fla. The purpose of this study is to determine the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of WSD0922-FU in subjects with recurrent glioblastoma, IDH wildtype (GBM), anaplastic astrocytoma, IDH wildtype (AA) and CNS metastases of non-small cell lung cancer (NSCLC).

A Study to Evaluate Fractionated Radiation Therapy Utilizing GRID Therapy for Locally-advanced Bulky Tumors

Rochester, Minn., Jacksonville, Fla. The purpose of this research is to study radiographic control at the 3 month time-point, the side effects (good & bad), survival outcomes and proof of this idea in patients who have had grid therapy for locally advanced bulky tumors of the heat and neck, thorax, abdomen and extremities.

Evaluate the Safety Tolerability Pharmacokinetics and Preliminary Evidence of Antitumor Activity of JAB-3312 Based Combination Therapies in Adult Patients with Advanced Solid Tumors

Jacksonville, Fla., Rochester, Minn., Scottsdale/Phoenix, Ariz. The purpose of this study is to demonstrate the safety and tolerability of JAB-3312 in combination with anti-PD-1 mAb or MEKi or KRASi or EGFR-TKI in patients with advanced solid tumors.

Profiling of Lung Cancer for Identification of Treatment Targets and Strategies

Jacksonville, Fla. The purpose of this research trail is to study the genetic alteration/mutation and immune profiling in surgical resected Non-small Cell Lung Cancer (NSCLC) tumor samplesand to investigate the correlation between genetic alteration/mutation status and tumor immune micro-environment.

Crizotinib in Treating Patients with Stage IB-IIIA Non-small Cell Lung Cancer that has been Removed by Surgery and ALK Fusion Mutations An ALCHEMIST Treatment Trial

Scottsdale/Phoenix, Ariz., Rochester, Minn. This randomized phase III trial studies how well crizotinib works and compares it to placebo in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called ALK. Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Tumors with this mutation may respond to treatments that target the mutation, such as crizotinib. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. It is not yet known if crizotinib may be an effective treatment for treating non-small cell lung cancer with an ALK fusion mutation.

Programa de cáncer de pulmón

Página inicial del departamentoSeccionesPanorama generalAnálisis y procedimientosEnfermedades tratadasMédicosMédicos por ubicación y especialidadGrupos especializadosConocimientos y categoríasCentros, viajes y alojamientoCostos y seguroNoticias de Mayo ClinicEnsayos clínicosInvestigaciónRemisiones

Investigación todo es por los pacientes

Secciones

Solicite una ConsultaPanorama generalAnálisis y procedimientosEnfermedades tratadasMédicosMédicos por ubicación y especialidadGrupos especializadosConocimientos y categoríasCentros, viajes y alojamientoCostos y seguroNoticias de Mayo ClinicEnsayos clínicosInvestigaciónRemisiones ORG-20461564 Departamentos y centros Centros y departamentos médicos Programa de cáncer de pulmón